Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
Authors:
- William P. TewWTWilliam P. Tew
- Michael W. SillMSMichael W. Sill
- Joan L. WalkerJWJoan L. Walker
- Angeles Alvarez SecordASAngeles Alvarez Secord
- Albert J. BonebrakeABAlbert J. Bonebrake
- Jeanne M. SchilderJSJeanne M. Schilder
- Ashley StuckeyASAshley Stuckey
- Laurel RiceLRLaurel Rice
- Krishnansu S. TewariKTKrishnansu S. Tewari
- Carol A. AghajanianCACarol A. Aghajanian
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 151 (2) , 257-263
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA 27469, CA 37517, 1 U10 CA180822, U10CA180868)
- Memorial Sloan Kettering Cancer Center (P30 CA008748)
This publication has 25 references indexed in Scilit:
- Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2014
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III TrialJournal of Clinical Oncology, 2014
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II ConsortiaJournal of Clinical Oncology, 2008
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous CancerJournal of Clinical Oncology, 2007
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinomaBritish Journal of Cancer, 2000
- Serum Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasms: Correlation with Patient SurvivalGynecologic Oncology, 1999
- Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant AscitesAnnals of Surgical Oncology, 1999